stoxline Quote Chart Rank Option Currency Glossary
  
Amylyx Pharmaceuticals, Inc. (AMLX)
18.71  -0.14 (-0.74%)    03-01 16:00
Open: 19.04
High: 19.2
Volume: 1,125,714
  
Pre. Close: 18.85
Low: 18.58
Market Cap: 1,267(M)
Technical analysis
2024-03-01 4:50:42 PM
Short term     
Mid term     
Targets 6-month :  23.3 1-year :  27.21
Resists First :  19.94 Second :  23.3
Pivot price 16.91
Supports First :  16.77 Second :  14.81
MAs MA(5) :  18.73 MA(20) :  16.54
MA(100) :  15.52 MA(250) :  21.1
MACD MACD :  0.9 Signal :  0.5
%K %D K(14,3) :  83.6 D(3) :  83
RSI RSI(14): 62
52-week High :  38.31 Low :  11.81
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMLX ] has closed below upper band by 22.7%. Bollinger Bands are 80.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 19.21 - 19.34 19.34 - 19.44
Low: 18.33 - 18.46 18.46 - 18.56
Close: 18.53 - 18.73 18.73 - 18.9
Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 01 Mar 2024
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn ... - PR Newswire

Fri, 01 Mar 2024
Kirby McInerney LLP Reminds Amylyx Pharmaceuticals, Inc. (AMLX) Investors of Class Action Filing and Encourages ... - Business Wire

Tue, 27 Feb 2024
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER - GlobeNewswire

Mon, 26 Feb 2024
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ... - GlobeNewswire

Mon, 26 Feb 2024
AMLX LAWSUIT ALERT: The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit ... - PR Newswire

Sat, 24 Feb 2024
Do Its Financials Have Any Role To Play In Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Stock Up Recently? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 68 (M)
Shares Float 55 (M)
Held by Insiders 13.7 (%)
Held by Institutions 98.5 (%)
Shares Short 5,440 (K)
Shares Short P.Month 5,440 (K)
Stock Financials
EPS 0.69
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.51
Profit Margin 12.9 %
Operating Margin 1.7 %
Return on Assets (ttm) 5.3 %
Return on Equity (ttm) 12.7 %
Qtrly Rev. Growth 395.5 %
Gross Profit (p.s.) 0
Sales Per Share 5.61
EBITDA (p.s.) 0.58
Qtrly Earnings Growth 0 %
Operating Cash Flow 12 (M)
Levered Free Cash Flow 38 (M)
Stock Valuations
PE Ratio 26.72
PEG Ratio 0.1
Price to Book value 2.86
Price to Sales 3.33
Price to Cash Flow 106.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android